Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00353379
Other study ID # GCO 95-0650
Secondary ID R01MH056140DATR
Status Terminated
Phase Phase 4
First received July 14, 2006
Last updated February 9, 2017
Start date September 1995
Est. completion date May 1997

Study information

Verified date February 2017
Source Icahn School of Medicine at Mount Sinai
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will determine the effectiveness of guanfacine in improving cognitive and functional impairments in schizotypal personality disorder.


Description:

Schizotypal personality disorder is a psychiatric condition that is characterized by deficiencies in interpersonal relationships and disturbances in thought patterns, appearance, and behavior. This disorder is different from schizophrenia. While some of the symptoms of the two disorders are similar, such as the tendency to have unusual beliefs and behaviors, people with schizotypal personality disorder do not experience hallucinations and are not significantly disconnected from reality, both of which are signature symptoms of schizophrenia. Guanfacine is a drug that is often used to treat high blood pressure and attention deficit hyperactivity disorder. There is evidence that guanfacine enhances cognition and diminishes impulsivity. This study will determine the effectiveness of guanfacine in improving symptoms of schizotypal personality disorder.

Participants in this 6-week, double-blind study will be randomly assigned to receive either guanfacine or placebo. Participants receiving guanfacine will remain on the drug for the duration of the study. The other participants will receive placebo for the duration of the study. Guanfacine dosages will not exceed 2 mg per day. All participants will report to the study site weekly for assessments of vital signs, study compliance, medication side effects, and psychological symptoms. Additional cognitive testing will be performed at week 6. Upon study completion, patients will return for a follow-up assessment.


Recruitment information / eligibility

Status Terminated
Enrollment 29
Est. completion date May 1997
Est. primary completion date May 1997
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria:

- Subjects must be male or female

- Medically and neurologically healthy (Medically healthy means that the patient does not have a major or partially treated medical condition that based on the judgment of the research clinician would either put the patient at increased risk and/or affect our findings. Common conditions include: high blood pressure, diabetes, uncontrolled asthma or COPD, abnormal heart rhythm, chronic viral infections. Neurologically healthy means that the patient has not experienced brain injury or head trauma associated with prolonged (e.g., > 10 minutes) loss of consciousness, seizures or other conditions based on the research clinician's judgment would either put the patient at increased risk and/or affect our findings.)

- Between 18 and 60 years of age

- Patients must also be medication free (at least 2 weeks) while participating in guanfacine, except for the following medications: NSAIDS (eg, Advil), Tylenol, Levothyroxine (if on stable dose for 1 month, no symptoms of hypothyroidism and normal thyroid labs), Non-centrally acting antihistamines, H2 blockers (eg, Zantac), PPIs (eg, Prilosec, Prevacid). Research physician will make judgment on case-by-case basis based on risk to subject, and potential confounding effect on data validity.

- Subjects in the SPD group must meet DSM-IV criteria for Schizotypal Personality Disorder.

- Subjects in the AvPD group must meet DSM-IV criteria for Avoidant Personality Disorder and not meet criteria for schizotypal, paranoid, and schizoid personality disorder. In addition, the AvPD group must have fewer than 2 schizotypal traits.

Exclusion Criteria:

- Subjects may not have a significant medical illness (ie, insulin dependent diabetes, gastric/duodenal ulcer), or significant neurological illness (ie epilepsy, CMS, CVA, focal neurological lesion).

- Any cardiovascular condition that, based on the research clinician's judgment (which includes cardiological consultation), would put the participant at increased risk will be considered an exclusion criteria. This would certainly include evidence by history or exam of heart block, tachyarrhythmia, angina, ventricular hypertrophy, those taking antihypertensives. Blood pressure parameters will be a >25% decrease in mean arterial systolic blood pressure from baseline, an orthostatic decrease in systolic blood pressure of 20 mm Hg and/or in diastolic blood pressure of 10 mm Hg, and heart rate parameter will be below 55 bpm.

- Participants are also excluded if they are more than 40% above ideal body weight. The weight limit helps insure that standard doses of guanfacine will not be given to patients who are extremely overweight who might then receive a lower concentration of these drugs in their central nervous system.

- Subjects must also have a corrected or uncorrected visual acuity of 20/40 or better.

- All participants meeting DSM IV criteria for any current or past history of sustained IV-substance dependence are excluded from the study.

- Participants must be free of substance abuse for at least six months.

Healthy Controls:

Inclusion Criteria:

- Healthy control subjects will be selected according to criteria noted in methods, and in age distribution comparable to our patients.

- Healthy controls will be matched to patients on gender and parental socioeconomic status.

- Healthy controls must be male or female between the ages of 18 and 60.

Exclusion criteria:

- for medical illness are identical to those of patients

- must not meet criteria for a current or lifetime DSM-IV diagnosis of bipolar disorder, schizophrenia, schizoaffective disorder, or any Axis II disorder.

- a current Axis I or II diagnosis or a family history of psychotic disorder will also be excluded. However, to avoid a group of HC's too highly groomed and unrepresentative of the general population we will not exclude HC subjects meeting criteria for a past Axis I diagnosis, such as adjustment disorder, dysthymic disorder, depressive disorder not otherwise specified, specific phobia, and sleep disorders. In addition subjects meeting criteria for a non-IV substance abuse disorder more than 6 months prior to enrollment will not be excluded.

Study Design


Intervention

Drug:
Guanfacine
Participants will take guanfacine for 6 weeks. Guanfacine dosages will not exceed 2 mg per day.
Placebo
Participants will take placebo for 6 weeks.

Locations

Country Name City State
United States Icahn School of Medicine at Mount Sinai New York New York

Sponsors (2)

Lead Sponsor Collaborator
Icahn School of Medicine at Mount Sinai National Institute of Mental Health (NIMH)

Country where clinical trial is conducted

United States, 

References & Publications (1)

McClure MM, Barch DM, Romero MJ, Minzenberg MJ, Triebwasser J, Harvey PD, Siever LJ. The effects of guanfacine on context processing abnormalities in schizotypal personality disorder. Biol Psychiatry. 2007 May 15;61(10):1157-60. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Performance on tests of sustained attention, episodic memory, and working memory Measured at Week 1
Primary Performance on tests of sustained attention, episodic memory, and working memory Measured at Week 4
Secondary Hamilton Depression Rating Scale Measured at Week 1
Secondary Hamilton Depression Rating Scale Measured at Week 2
Secondary Hamilton Depression Rating Scale Measured at Week 3
Secondary Hamilton Depression Rating Scale Measured at Week 4
Secondary Hamilton Depression Rating Scale Measured at Week 5
Secondary Positive and Negative Symptom Scale Measured at Week 1
Secondary Positive and Negative Symptom Scale Measured at Week 2
Secondary Positive and Negative Symptom Scale Measured at Week 3
Secondary Positive and Negative Symptom Scale Measured at Week 4
Secondary Positive and Negative Symptom Scale Measured at Week 5
Secondary Clinical Global Impression Scale Measured at Week 1
Secondary Clinical Global Impression Scale Measured at Week 2
Secondary Clinical Global Impression Scale Measured at Week 3
Secondary Clinical Global Impression Scale Measured at Week 4
Secondary Clinical Global Impression Scale Measured at Week 5
See also
  Status Clinical Trial Phase
Recruiting NCT06367907 - Biological Effects of Schema Therapy N/A
Recruiting NCT05964296 - The Impact of the Use of the MAURISSE Application in People Suffering From an Addiction. N/A
Completed NCT02518906 - Evaluation of AIT Study N/A
Not yet recruiting NCT02126787 - Short-term, Intensive Psychodynamic Group Therapy Versus Cognitive-behavioral Group Therapy in the Day Treatment N/A
Active, not recruiting NCT05018312 - Modified Collaborative Assessment VS Standard Assessment on Readiness For Psychotherapy Among Patients With Anxiety N/A
Completed NCT04466163 - Strengthening the Healthy Adult Mode: a Case Experimental Study Exploring the Effects of a New Schema Therapy Protocol in an Adult Outpatient Population. N/A
Not yet recruiting NCT03608449 - Doing More With Less": Optimizing Psychotherapeutic Services in the Mental Health System N/A
Recruiting NCT06415812 - Evolutionary Systems Therapy for Personality Pathology N/A
Completed NCT05601063 - Ascertaining Diagnosis Classification With Elicited Speech
Completed NCT03768674 - Extreme Challenges - Psychopathology & Treatment Experiences Among Severly Selfharming Inpatients in Norway
Completed NCT02308462 - Implementation and Evaluation of a Family-based Intervention Program for Children of Mentally Ill Parents N/A
Terminated NCT00400933 - Evaluation of a Six-session Psycho-education Group Program Phase 1
Completed NCT04694482 - The Impact of the COVID-19 (SARS-CoV-2 Disease) on Psychopathology
Recruiting NCT05503745 - MICBT for Non-underweight Adults With Eating Disorders N/A
Completed NCT01428349 - Matching Cognitive Remediation to Cognitive Deficits in Substance-Abusing Inmates N/A
Active, not recruiting NCT00378248 - Ullevål PersonalityProject N/A
Recruiting NCT06182787 - Development of a Model for Digital Monitoring of the Mental State of the Hospitalized Patient
Completed NCT02573246 - Neuromodulation Enhanced Cognitive Restructuring: A Proof of Concept Study N/A
Not yet recruiting NCT02397187 - Efficacy of a Structured, Dimension-based, STI in De-compensated Personality-disorder, Hospitalized, Patients N/A
Completed NCT00458094 - Peer Support for Increasing Physical Activity in People With Serious Mental Illnesses N/A